Table 3.
Plasma triglycerides and lipoprotein (LDL, HDL, and VLDL) level profile of WKY, SHR control, and SHR diabetic treated groups with irbesartan, pioglitazone, adiponectin, and a combination of adiponectin with irbesartan or pioglitazone.
| Groups | Lipid profile | |||
|---|---|---|---|---|
| Triglycerides (mg/dL) | Total cholesterol (mg/dL) | HDL (mg/dL) | LDL (mg/dL) | |
| WKY+CNT | 50.75 ± 4.09 | 61.25 ± 2.29 | 16.33 ± 1.2 | 36.25 ± 1.8 |
| SHR+CNT | 84.80 ± 11.32! | 149.96 ± 17.54! | 67.64 ± 3.97! | 97.08 ± 6.33! |
| SHR+STZ | 172.4 ± 14.48∗ | 197.72 ± 12.72∗ | 42.02 ± 4.63∗ | 122.49 ± 6.01∗ |
| SHR+STZ+Irb | 153.9 ± 10.5δ# | 166.84 ± 15.0δ# | 59.78 ± 4.88δ# | 108.56 ± 7.97δ# |
| SHR+STZ+Pio | 147.2 ± 10.7δж | 153.98 ± 11.64δж | 72.89 ± 2.85δж | 98.96 ± 7.50δ |
| SHR+STZ+Adp | 93.20 ± 8.29δ | 129.60 ± 12.19δ | 79.22 ± 3.96δ | 96.03 ± 5.20δ |
| SHR+STZ+Irb+Adp | 85.25 ± 2.35δ | 136.57 ± 5.7δ | 79.25 ± 4.1δ | 95.28 ± 4.5δ |
| SHR+STZ+Pio+Adp | 73.25 ± 4.5δζ | 119.25 ± 6.7δζ | 77.28 ± 5.7δ | 91.25 ± 5.4δ |
Notes: the values are presented as the mean ± SEM (n = 6) in each group and were analyzed by one-way ANOVA followed by Bonferroni post hoc test. Values with P < 0.05 were considered statistically significant during and at the end of treatment. ! indicates significant difference (P < 0.05) between the SHR and WKY control groups. ∗ indicates significant difference (P < 0.05) in comparison to the SHR control group. δ indicates significant difference (P < 0.05) of the diabetic Irb, Pio, Adp, Irb+Adp, and Pio+Adp groups in comparison to the SHR diabetic control group. # indicates significant difference (P < 0.05) between the diabetic Irb and Adp groups. ж indicates a significant difference (P < 0.05) between the diabetic Pio and Adp groups. ζ indicates a significant difference (P < 0.05) of the diabetic Adp group in comparison to the diabetic Pio+Adp group at days 21 and 28.